MSF Field Research > 1 Published Research and Commentary > TB > Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis.

Please use this identifier to cite or link to this item: http://hdl.handle.net/10144/91158
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!



Download this article:
View/Open File Description Size Format
Thumbnail
View/Open
Matthys Outcomes Resist TB PLoS One.pdf92KbAdobe PDF

Title: Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis.
Authors: Matthys, Francine
Rigouts, Leen
Sizaire, Vinciane
Vezhnina, Natalia
Lecoq, Maryvonne
Golubeva, Vera
Portaels, Françoise
Van der Stuyft, Patrick
Kimerling, Michael
Affiliation: Epidemiological and Disease Control Unit, Department of Public Health, Institute of Tropical Medicine, Antwerp, Belgium. fmatthys@itg.be
Citation: Outcomes after chemotherapy with WHO category II regimen in a population with high prevalence of drug resistant tuberculosis. 2009, 4 (11):e7954 PLoS ONE
Publisher: PLoS
Journal : PloS One
Issue date: Dec-2009
URI: http://hdl.handle.net/10144/91158
DOI: 10.1371/journal.pone.0007954
PubMed ID: 19956770
Abstract: Standard short course chemotherapy is recommended by the World Health Organization to control tuberculosis worldwide. However, in settings with high drug resistance, first line standard regimens are linked with high treatment failure. We evaluated treatment outcomes after standardized chemotherapy with the WHO recommended category II retreatment regimen in a prison with a high prevalence of drug resistant tuberculosis (TB). A cohort of 233 culture positive TB patients was followed through smear microscopy, culture, drug susceptibility testing and DNA fingerprinting at baseline, after 3 months and at the end of treatment. Overall 172 patients (74%) became culture negative, while 43 (18%) remained positive at the end of treatment. Among those 43 cases, 58% of failures were determined to be due to treatment with an inadequate drug regimen and 42% to either an initial mixed infection or re-infection while under treatment. Overall, drug resistance amplification during treatment occurred in 3.4% of the patient cohort. This study demonstrates that treatment failure is linked to initial drug resistance, that amplification of drug resistance occurs, and that mixed infection and re-infection during standard treatment contribute to treatment failure in confined settings with high prevalence of drug resistance.
Language: en
ISSN: 1932-6203
Rights: Published by Public Library of Science, http://www.plosone.org/ Archived on this site by Open Access permission
Appears in topics:TB

Related articles on PubMed
bullet
Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries.
Espinal MA, Kim SJ, Suarez PG, Kam KM, Khomenko AG, Migliori GB, Baéz J, Kochi A, Dye C, Raviglione MC
2000 May 17
bullet
[Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H
2003 Oct
bullet
Tuberculosis retreatment category predicts resistance in hospitalized retreatment patients in a high HIV prevalence area.
Schreiber YS, Herrera AF, Wilson D, Wallengren K, Draper R, Muller J, Dawood H, Doucette S, Cameron DW, Alvarez GG
2009 Oct
bullet
bullet
The Directly Observed Therapy Short-Course (DOTS) strategy in Samara Oblast, Russian Federation.
Balabanova Y, Drobniewski F, Fedorin I, Zakharova S, Nikolayevskyy V, Atun R, Coker R
2006 Mar 23
See all 102 articles

All items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.

 

OR Logo Powered by Open Repository

My MSF

MSF logo MSF Field Research

Feb 4, 2012